COVID-19 Vaccine CoronaVac^®Hub

Conditioned market authorization in China on February 5, 2021

üThe results of pre-clinical and clinical research trials were published in Science and Lancet Infect Diseases.

üThe result of Phase Ⅰ/Ⅱ/Ⅲ Clinical Trial showed that CoronaVac® has good safety and immunogenicity for all ages.

üThe Phase Ⅲ Clinical Trial and real-world studies showed that vaccination with CoronaVac has a significant impact on reducing the incidence, hospitalization and death rate caused by COVID-19 infection.

üThe inactivated COVID-19 Vaccine, CoronaVac®, was approved for WHO Emergency Use Listing (EUL).

üThe annual production capacity is over 2 billion doses, and CoronaVac® has been approved for emergency use in over 50 countries/regions/organizations around the world. 

üAs of November 2021, the cumulative global supply of CoronaVac more than 2.3 billion doses, and the cumulative vaccinated doses reached 1.9 billion. It is currently the largest supplied and vaccinated COVID-19 vaccine in China and worldwide, and the China’s COVID-19 vaccine with the largest export amount globally.

• SINOVAC’s EV71 vaccine Inlive® is approved for children aged from 6 to 71 months
  2021/06/12
• Sinovac Biotech Announces Issuance of GMP Certificate for EV71 Vaccine
  2016/01/28
• Sinovac Obtains New Drug Certificate and Production License for EV71 Vaccine
  2016/01/04
• Sinovac Receives Site Inspection Notification for EV71 Vaccine Production Facilities
  2015/05/14
• Sinovac Receives Notification of China Government Grant for EV71 Vaccine Project
  2014/04/24
• Sinovac’s EV71 Vaccine Phase III Clinical Trial Results Published in New England Journal of Medicine
  2014/02/27
• Sinovac Files New Drug Application for EV71 Vaccine and Receives Filing Acceptance from Beijing Drug Administration
  2013/05/30
• Sinovac EV71 Vaccine Phase III Top-Line Results Presented at 13th Annual World Vaccine Congress & Expo
  2013/04/18
• Sinovac Reports Preliminary Top-Line Results from Phase III Clinical Trial for EV71 Vaccine Candidate Against Hand, Foot and Mouth Disease
  2013/03/14
• Sinovac Reports Progress in EV71 Vaccine Phase III Clinical Trial and Commercialization Preparation Status
  2012/06/26
• Sinovac Reports Progress in EV71 Vaccine Phase III Clinical Trial
  2012/06/12
• Sinovac's EV71 Vaccine Phase I Clinical Data for the Prevention of Epidemic Hand, Foot, Mouth Disease Published in Vaccine
  2012/03/29
• Sinovac Commences the Phase III Clinical Trial for its EV71 Vaccine Against Hand, Foot and Mouth Disease
  2012/01/10
• Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease
  2011/11/09
• Sinovac Commences Phase II Clinical Trial for EV71 Vaccine
  2011/06/28
• Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD)
  2011/05/25
• Sinovac Reports Positive Preliminary Phase I Clinical Trial Results for EV71 Vaccine in Adult Group
  2011/03/10